combat first look analyst day prep esmo oral week
gener juli revers split adjust
quarterli ep may add full year result due round
increas share count
look like stage set next step pancreat cancer
yesterday biolinerx host annual analyst day new york
happen conjunct releas esmo-io abstract
on-going studi event focus
two primari compon thorough review pancreat
cancer space kol talia golan chaim sheba medic
center importantli dr golan comment specif
rather treatment landscap evolv
encourag first look tripl combin data second-
line pancreat patient esmo-io abstract recal phase
portion studi test use keytruda
chemotherapi detail matur data
set announc oral present esmo-io decemb
previous disclos
combat data snapshot esmo abstract low bar success
discuss abstract data combat short
like first look difficult treat popul stress
enough data releas abstract earli small number
patient first albeit encourag incomplet look
cutoff abstract septemb patient
enrol evalu safeti efficaci first look
diseas control rate dcr observ
includ four patient partial respons pr
eight stabl diseas sd
median os reach yet guidanc
remain provid data
seriou advers event sae observ patient
two discontinu due safeti profil consist
individu profil compon note intens
interest observ first look expect
detail esmo patient pr sd
saw initi increas tumor marker ca follow
decreas tumor shrinkag began transient increas
sure volatil day yesterday face valu data
appear reson well investor yesterday share
vs xbi could concern first
still remain low expect pancreat cancer overal
second investor may balk high sae rate though
point like due chemo compon
therapi lastli earli posit data hand
typic financ overhang argument may rekindl howev
cash million manag believ provid
runway data repres first readout tripl
combin trial differ modal second-lin pancreat
compani like explor pivot path pancreat
space addit signal seek opportun cold tumor
potenti busi develop activ recal combat studi
conduct collabor merck rate
addit studi conduct collabor
genentech rhhbi rate either could lead
signfiic partnership belief
definit distribut analyst rate analyst certif disclosur pleas refer page report
kol comment much need learn process pancreat continu dr golan discuss multipl therapeut
approach pancreat cancer also show broad list failur indic includ greatli
underwhelm respons immunotherapi overal consid patient seer databas pancreat
cancer rise howev increment albeit minor benefit observ treatment front end
outlier patient live month longer increas patient die within two month decreas
therapeut field still scratch surfac regard therapeut benefit consid initi target
popul dr golan indic less patient make second-lin therapi addit
believ strongli field reach limit chemotherapi includ use triplet therapi associ
signific toxic real world exampl patient achiev signific pr succumb
toxic massiv chemotherapi regimen side note highlight someth consid assess
combat data sae profil disclos abstract pancreat field continu develop face larg
number failur dr golan encourag compani look neoadjuv set development therapi
could also make quit easier recruit patient clinic studi look therapeut approach increment
advanc util biomark approach brca ddr howev small percentag popul
broader therapeut approach need dr golan acknowledg scientif rational behind respect moa
skeptic toward recent effort target tumor metabol investig efficaci l-
asparaginas although approach shown promis respons investig combin
chemotherapi move small phase directli larg phase biomark identifi guid
patient select discuss previous pancreat cancer remain tumor type immun desert howev
dr golan talk broad complex tumor microenviron tme pancreat discuss evid primari
tumor tumor reactiv cell tme inact examin wise tumor feel like rock base
mechan action break tme cell environ believ prospect encourag base previous
disclos phase data show strong infiltr cell tumor follow treatment keytruda
remind respons rate keytruda alon essenti zero specif speak
stress independ dr golan applaud compani use biopsi strategi help identifi potenti marker
drive efficaci base treatment regimen also direct per se question ask clinic
benefit achiev stabl diseas sd dr golan indic come durat patient specif
sd last greater three month clinic meaning still highlight low bar success pancreat
dr golan commentari also focus continu unansw question regard innov combin dr
golan indic pancreat cancer alway need chemotherapi howev open question
balanc potenti therapeut benefit signific toxic much chemotherapi question could
answer effect role immunotherapi decis need made base preclin model
empir clinic evid regard best way sequenc therapi mechanist goal chemo
immunotherapi chemo provid debulk effect well signific present antigen immun
system epitop spread tumor cell die goal reduc chemotherapi burden patient still provid
meaning benefit experi trial conduct assess start stop chemotherapi let
immunotherapi approach take control
encourag detail around combat esmo abstract releas forget current benchmark new
combat data releas continu caution investor make intrastudi comparison though import
point today one therapi approv second line set tripl chemo combin
approv base orr approxim dcr median overal surviv
month regard combat data figur show swimmer plot patient studi indic type
respons time therapi patient note earli termin includ respond recal two patient
withdrew due sae howev manag note one patient particular pr respond termin
studi becam non-compli therefor data could record
swimmer plot combat cohort esmo-io abstract data
portray anoth fashion next two figur contain waterfal plot show chang target lesion size well
spider plot show chang lesion size time respect note though small number
patient see level tumor size reduct stabl diseas would realli expect patient popul
continu mention approv second-lin therapi chart highlight
result multipl studi second-lin pancreat set base earli combat data thu far come next
week appear may surpass studi current on-going therapeut approach
second-lin pancreat studi combat may readi surpass
approach key data readout start decemb quiet first half year term data
releas approach multipl catalyst across on-going program detail studi
report summari
top-line data phase tripl combin arm trial
pancreat cancer patient expect deliv esmo-io confer decemb note part
data releas earlier confer embargo lift abstract oral present
actual confer expect contain import addit result studi data cutoff abstract submiss
much earlier one oral present manag disclos also trial remain track deliv
os data
data updat collabor genentech-roch rhhbi rate expect could valid
evalu combin atezolizumab two phase studi pancreat gastric cancer
although compani limit access data genentech announc studi complet
plan report result
interim analysi phase aml consolid blast studi expect recal studi event
driven relaps timelin report data fluid base number current event compani
expect abl report data later initi project year-end biolin plan meet
regul discuss optim path forward r/r aml accumul long term data
top-line result genesi expect recal compani believ stem cell mobil
effici initi pathway registr trial continu expect note result replic lead portion
studi registr probabl bolster well potenti use indic beyond multipl myeloma
initi efficaci phase unresect solid tumor expect current trial
conduct site israel compani plan open site dose escal
complet success sepetemb posit safeti recommend dose determin note studi
complet without reach dlt move quickli part
accumul posit data favor combat posit outcom studi conduct combin merck
rate expect build upon dual combin data report last year prompt expans
tripl combo addit posit clinic data clinic activ extend surviv hard treat popul
dual combin studi collabor md anderson report support rational
behind tripl combo remind investor key differ among dual tripl combin studi
favor posit outcom arm dual combin enrol patient receiv differ line therapi
tripl combo arm enrol patient diagnos metastat diseas begin
popul homogen power observ report significantli strengthen deep
dive rational data support review prior note investor day highlight
profil project confid overal program belief would like highlight
report consist posit data multipl clinic front pois deliv clinic shift two import
therapeut area autolog hematopoiet stem cell mobil pancreat cancer delin
profil suitabl combin multipl oncolog indic line compani strategi develop
posit combact data begin open opportun partnership licenc agreement recal
grant fda-orphan drug design three indic investig pancreat cancer aml stem
cell mobil regardless street seem undervalu possibl poor expect surround
pancreat cancer indic place compani show-me-stag believ upcom data
contribut highlight multipl aspect opportun
phase blast aml consolid robust interim data releas expect mention potenti
interim data releas expect larg random control phase studi consolid therapi
aml patient first remiss top-line data given import interim analysi futur develop
program includ possibl phase trial manag make sure studi reach highest possibl power
releas data note interim provid enough insight util aml patient
remiss give confid use r/r aml recal phase blast studi demonstr
plu high dose cytarabin ara-c result increas surviv rate r/r aml patient compar cytarabin
alon month vs month respect eha orr regimen safe well toler
current long-term surviv evalu manag pursu indic potenti discuss
fda defin next step develop later year
phase genesi on-going enrol progress expect target patient site complet
enrol expect top-line data expect recal posit data lead-in portion
trial present ebmt follow dmc approv studi move second part random
control part studi compar combin plu g-csf vs g-csf alon soc preliminari data
highlight increas clinic benefit ad soc vs soc stand-alone therapi context autolog
transplant multipl myeloma patient specif mobil six million hsc usual requir eight inject
soc four apheresi session plu soc could reach similar stem cell mobil level within fewer apheresi
session two one suggest potenti cost-effect opportun g-csf previou result confirm
larger portion trial part combo therapi could becom real therapeut opportun autolog bone
marrow transplant potenti deploy multipl clinic set includ nhl believ posit data
would also derisk oncolog program addit mechanist valid
decemb top-lin result phase tripl combo pancreat cancer trial keytruda
chemotherapi compani collabor merck rate
potenti interim result phase aml consolid studi
initi safeti result part phase trial
progression-fre surviv overal surviv os data patient trial
top-lin result phase genesi registr trial stem-cel mobil
valuat risk price target achiev reiter buy rate price target note still
rel larg delta current share price target also larg attribut low number
share outstand post-revers split valuat base clinic net present valu npv model current
driven compani lead asset model allow us flex multipl assumpt affect drug potenti
commerci profil factor could imped reach price target includ fail inconclus clinic trial inabl
compani secur adequ fund progress drug develop pathway
us million except per share data
product royalti
provis tax
particip prefer stock
net incom common
sec file wainwright estim
start figur usd
juli revers split adjust
us million except per share data
product royalti
provis tax
particip prefer stock
net incom common
sec file wainwright estim
start figur usd
juli revers split adjust
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori biolinerx ltd blrx-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
joseph pantgini ph certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli
relat specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur biolinerx ltd
includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
biolinerx ltd
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens biolinerx ltd non-invest bank servic previou
firm affili receiv compens biolinerx ltd invest bank servic within twelv month
seek compens compani mention report invest bank servic within three
month follow public research report
firm make market biolinerx ltd date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
